An overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.
Latest Update: June 2022
MorphoSys' Clinical Programs
Selection of our Partners’ Clinical Programs
Gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration. It is being studied by Roche in several Phase 3 trials for the treatment of people living with Alzheimer’s disease and prevention of Alzheimer’s. Gantenerumab received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA).
Otilimab is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that is developed by GSK for the treatment of rheumatoid arthritis (Phase 3).
Ianalumab (VAY736) is an antibody directed against BAFF-R that is being investigated by Novartis in several indications including Sjögren’s syndrome, Autoimmune Hepatitis and Systemic Lupus Erythematosus (SLE). Ianalumab is currently in phase 2 clinical development and is expected to enter phase 3 clinical development in 2022 (Lupus Nephritis, Sjögren’s syndrome).
Abelacimab (MAA868) is an antibody directed against Factor XI that is being investigated by Anthos Therapeutics in a phase 3 clinical program for the prevention of venous thromboembolism (VTE) and cancer associated thrombosis (CAT).
Felzartamab is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HIBio) obtained exclusive rights to develop and commercialize felzartamab across all indications worldwide, with the exception of Greater China. On behalf of HIBio, MorphoSys is evaluating felzartamab for patients with two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy (M-PLACE and NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial). I-Mab Biopharma holds the exclusive regional rights to develop and commercialize felzartamab in Greater China and is studying felzartamab in relapsed/refractory multiple myeloma.
Setrusumab (BPS804) is an antibody directed against sclerostin that is currently being investigated by Ultragenyx and Mereo Biopharma in a phase 2/3 clinical study for the treatment of osteogenesis imperfecta.
NOV-8 (CMK389) is being investigated by Novartis for the treatment of pulmonary sarcoidosis (Phase 2) and severe atopic dermatitis (also Phase 2).
Bimagrumab is currently being investigated by Novartis and Versanis Bio in Phase 2 for the treatment of Type 2 diabetes.
NOV-9 (LKA651) is also currently being investigated by Novartis in Phase 2 for the treatment of diabetic eye diseases.
NOV-14 (CSJ117) is currently under investigation by Novartis for the treatment of Asthma (Phase 2) and chronic obstructive pulmonary disease (COPD; also currently in Phase 2).
MOR210 is a human antibody directed against C5aR1, the receptor of the complement factor C5a. Human Immunology Biosciences (HIBio) obtained exclusive worldwide rights to develop and commercialize MOR210 across all indications worldwide, with the exception of Greater China and South Korea. I-Mab Biopharma holds the exclusive rights for MOR210 in Greater China and South Korea and is currently investigating MOR210 for the treatment of relapsed or refractory advanced solid tumors (Phase 1).
OUR LIGHTHOUSE PROGRAMS
Tafasitamab is a humanized monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies.
Pelabresib, also known as CPI-0610, is a BET inhibitor that is being studied as a treatment for Myelofibrosis.